3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Plasma cell
1
Lymphoid
1
Classical hematology
1
Conditions
Lymphoma
6
Neoplasms, Plasma Cell
4
Lymphoma, Non-Hodgkin
4
Leukemia
4
Infections
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Waldenstrom Macroglobulinemia
2
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neutropenia
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Intraocular Lymphoma
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Thrombocythemia, Essential
1
Recurrence
1
Primary Myelofibrosis
1
Precancerous Conditions
1
Polycythemia Vera
1
Interventions
Cyclophosphamide
40
fludarabine
36
fludarabine phosphate
28
Tacrolimus
20
Whole-Body Irradiation
18
Mycophenolic Acid
18
Busulfan
18
Melphalan
16
thymoglobulin
14
Rituximab
13
Antilymphocyte Serum
12
venetoclax
11
Thiotepa
10
Nivolumab
9
Methotrexate
9
Granulocyte Colony-Stimulating Factor
9
Stem Cell Transplantation
8
Peripheral Blood Stem Cell Transplantation
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Cytarabine
7
Azacitidine
7
AP 1903 reagent
7
Filgrastim
6
Dexamethasone
6
aldesleukin
5
Mesna
5
Ipilimumab
5
Interleukin-2
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Ciprofloxacin
×
Lymphoid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled